News >

Change in Treatment Administration May Reduce Osteonecrosis in Pediatric ALL

Jason Harris
Published: Friday, Jan 26, 2018

The method of treatment administration in the JACLS ALL-97 and ALL-02 trials may have contributed to a lower incidence of osteonecrosis in Japanese children with acute lymphoblastic leukemia (ALL), according to a retrospective analysis published in the Journal of Clinical Oncology.

“Not only the total amount of dexamethasone, but also how dexamethasone and L-asparaginase are administered, which affects the clearance of dexamethasone, may be associated with the incidence of osteonecrosis in patients with ALL. Future studies will be required to determine whether the development of osteonecrosis is associated with the combined treatment of corticosteroids and L-asparaginase,” Sakamoto et al concluded.
Sakamoto K, Imamura T, Kihira K, et al. Low Incidence of osteonecrosis in childhood acute lymphoblastic leukemia treated with ALL-97 and ALL-02 study of Japan Association of Childhood Leukemia Study Group [published online January 23, 2018]. J Clin Oncol doi: 10.1200/JCO.2017.75.5066.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication